Loading
RFX7 (DNA-binding protein RFX7) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Burkitt lymphoma. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Transcription factor. Acts as a transcriptional activator by binding to promoter regions of target genes, such as PDCD4, PIK3IP1, MXD4, PNRC1, and RFX5. Plays a role in natural killer (NK) cell maintenance and immunity. May play a role in the process of ciliogenesis in the neural tube and neural tube closure. Location: Nucleus (UniProt). Locus 15q21.3 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"RFX7" OR ABSTRACT:"RFX7" OR TITLE:"regulatory factor X7" OR ABSTRACT:"regulatory factor X7" OR TITLE:"DNA-binding protein RFX7" OR ABSTRACT:"DNA-binding protein RFX7" OR TITLE:"FLJ12994" OR ABSTRACT:"FLJ12994" OR TITLE:"RFXDC2" OR ABSTRACT:"RFXDC2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RFX7, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/rfx7.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rfx7.json. Licence CC BY-NC 4.0.